242 related articles for article (PubMed ID: 19787276)
1. Promoter hypermethylation of the p16 and Wif-1 genes as an independent prognostic marker in stage IA non-small cell lung cancers.
Yoshino M; Suzuki M; Tian L; Moriya Y; Hoshino H; Okamoto T; Yoshida S; Shibuya K; Yoshino I
Int J Oncol; 2009 Nov; 35(5):1201-9. PubMed ID: 19787276
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
3. WIF-1 promoter region hypermethylation as an adjuvant diagnostic marker for non-small cell lung cancer-related malignant pleural effusions.
Yang TM; Leu SW; Li JM; Hung MS; Lin CH; Lin YC; Huang TJ; Tsai YH; Yang CT
J Cancer Res Clin Oncol; 2009 Jul; 135(7):919-24. PubMed ID: 19085002
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance of WIF1 hypermethylation in NSCLC, a meta-analysis and literature review.
Guo H; Zhou S; Tan L; Wu X; Wu Z; Ran R
Oncotarget; 2017 Jan; 8(2):2550-2557. PubMed ID: 27911280
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation of Wnt inhibitory factor-1 in patients with lung cancer: A systematic meta-analysis.
Zheng Y; Li X; Jiang Y; Xu Y; Song B; Zhou Q; Liang X; Yang X
Medicine (Baltimore); 2016 Dec; 95(49):e5433. PubMed ID: 27930522
[TBL] [Abstract][Full Text] [Related]
6. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients.
Bradly DP; Gattuso P; Pool M; Basu S; Liptay M; Bonomi P; Buckingham L
Diagn Mol Pathol; 2012 Dec; 21(4):207-13. PubMed ID: 23111194
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer.
Zhang X; Yang X; Wang J; Liang T; Gu Y; Yang D
Int J Clin Exp Pathol; 2015; 8(9):11452-7. PubMed ID: 26617874
[TBL] [Abstract][Full Text] [Related]
8. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer.
Kim DH; Nelson HH; Wiencke JK; Zheng S; Christiani DC; Wain JC; Mark EJ; Kelsey KT
Cancer Res; 2001 Apr; 61(8):3419-24. PubMed ID: 11309302
[TBL] [Abstract][Full Text] [Related]
9. WNT inhibitory factor 1 promoter hypermethylation is an early event during gallbladder cancer tumorigenesis that predicts poor survival.
Lin B; Hong H; Jiang X; Li C; Zhu S; Tang N; Wang X; She F; Chen Y
Gene; 2017 Jul; 622():42-49. PubMed ID: 28438695
[TBL] [Abstract][Full Text] [Related]
10. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer.
Bearzatto A; Conte D; Frattini M; Zaffaroni N; Andriani F; Balestra D; Tavecchio L; Daidone MG; Sozzi G
Clin Cancer Res; 2002 Dec; 8(12):3782-7. PubMed ID: 12473590
[TBL] [Abstract][Full Text] [Related]
11. WNT pathway in oral cancer: epigenetic inactivation of WNT-inhibitors.
Pannone G; Bufo P; Santoro A; Franco R; Aquino G; Longo F; Botti G; Serpico R; Cafarelli B; Abbruzzese A; Caraglia M; Papagerakis S; Lo Muzio L
Oncol Rep; 2010 Oct; 24(4):1035-41. PubMed ID: 20811686
[TBL] [Abstract][Full Text] [Related]
12. Hypermethylation of p16(INK4a) and p15(INK4b) genes in non-small cell lung cancer.
Kurakawa E; Shimamoto T; Utsumi K; Hirano T; Kato H; Ohyashiki K
Int J Oncol; 2001 Aug; 19(2):277-81. PubMed ID: 11445839
[TBL] [Abstract][Full Text] [Related]
13. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
Kim JS; Kim JW; Han J; Shim YM; Park J; Kim DH
Cancer Res; 2006 Apr; 66(8):4049-54. PubMed ID: 16618724
[TBL] [Abstract][Full Text] [Related]
14. [The role of secreted Wnt-antagonist genes hypermethylation in early detection of colorectal tumor].
Qi J; Zhu YQ; Luo J; Tao WH
Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(28):1954-7. PubMed ID: 17923031
[TBL] [Abstract][Full Text] [Related]
15. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients.
Buckingham L; Penfield Faber L; Kim A; Liptay M; Barger C; Basu S; Fidler M; Walters K; Bonomi P; Coon J
Int J Cancer; 2010 Apr; 126(7):1630-9. PubMed ID: 19795445
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the prognostic value of methylation status and expression levels of FHIT, GSTP1 and p16 in non-small cell lung cancer in Egyptian patients.
Haroun RA; Zakhary NI; Mohamed MR; Abdelrahman AM; Kandil EI; Shalaby KA
Asian Pac J Cancer Prev; 2014; 15(10):4281-7. PubMed ID: 24935385
[TBL] [Abstract][Full Text] [Related]
17. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.
Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV
Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699
[TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation for molecular nodal staging in non-small cell lung cancer.
Safar AM; Spencer H; Su X; Cooney CA; Shwaiki A; Fan CY
Arch Pathol Lab Med; 2007 Jun; 131(6):936-41. PubMed ID: 17550322
[TBL] [Abstract][Full Text] [Related]
19. A prognostic DNA methylation signature for stage I non-small-cell lung cancer.
Sandoval J; Mendez-Gonzalez J; Nadal E; Chen G; Carmona FJ; Sayols S; Moran S; Heyn H; Vizoso M; Gomez A; Sanchez-Cespedes M; Assenov Y; Müller F; Bock C; Taron M; Mora J; Muscarella LA; Liloglou T; Davies M; Pollan M; Pajares MJ; Torre W; Montuenga LM; Brambilla E; Field JK; Roz L; Lo Iacono M; Scagliotti GV; Rosell R; Beer DG; Esteller M
J Clin Oncol; 2013 Nov; 31(32):4140-7. PubMed ID: 24081945
[TBL] [Abstract][Full Text] [Related]
20. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
